Study S003383

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GMA106 IN HEALTHY, OVERWEIGHT AND OBESE ADULTS

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05054530
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 73
Start: 2021-11-11
Primary completion: 2023-11-17
Lead sponsor: Gmax Biopharm Australia Pty Ltd.
Conditions: Overweight and Obesity
Interventions: DRUG:GMA106 Injection; DRUG:GMA106 Matching Placebo
Results posted: FALSE

Registered primary outcomes

Nature, incidence and severity of treatment emergent adverse events [up to 150±5 days post injection]
Nature, incidence and severity of treatment emergent adverse events [up to 227±5 days post first injection]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.